These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 39127338)

  • 1. Advances in and prospects of immunotherapy for prostate cancer.
    Liu D; Wang L; Guo Y
    Cancer Lett; 2024 Oct; 601():217155. PubMed ID: 39127338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
    Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
    Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
    Anker JF; Naseem AF; Mok H; Schaeffer AJ; Abdulkadir SA; Thumbikat P
    Nat Commun; 2018 Apr; 9(1):1591. PubMed ID: 29686284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
    Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer.
    Zhang XJ; Yu Y; Zhao HP; Guo L; Dai K; Lv J
    World J Gastroenterol; 2024 Apr; 30(16):2195-2208. PubMed ID: 38690024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.
    Porter LH; Harrison SG; Risbridger GP; Lister N; Taylor RA
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106571. PubMed ID: 38909866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the tumor-immune microenvironment in prostate cancer.
    Dong L; Myers KV; Pienta KJ
    Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    De Velasco MA; Kura Y; Fujita K; Uemura H
    Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
    Jansen CS; Prokhnevska N; Kissick HT
    Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
    Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
    Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.